Thus, the lack of a medical therapy to treat ARDS, and the fact that one-third of patients with IBD do not respond to therapy (71) highlight the need for the development of an alternative therapeutic such as PR1P to treat these common and debilitating diseases that are characterized by inflammation and VEGF dysregulation. The gene discussed is VEGFA; the disease is acute respiratory distress syndrome.